{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T14:17:27Z","timestamp":1743085047848,"version":"3.40.3"},"publisher-location":"Berlin, Heidelberg","reference-count":51,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642721557"},{"type":"electronic","value":"9783642721533"}],"license":[{"start":{"date-parts":[[1998,1,1]],"date-time":"1998-01-01T00:00:00Z","timestamp":883612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1998,1,1]],"date-time":"1998-01-01T00:00:00Z","timestamp":883612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998]]},"DOI":"10.1007\/978-3-642-72153-3_3","type":"book-chapter","created":{"date-parts":[[2011,11,9]],"date-time":"2011-11-09T17:37:06Z","timestamp":1320860226000},"page":"35-56","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Trials with Blocked Ricin Immunotoxins"],"prefix":"10.1007","author":[{"given":"J. E.","family":"O\u2019Toolei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Esseltine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. J.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Grossbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"3_CR1","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Anderson","year":"1984","unstructured":"Anderson KC, Slaughenhoupt B, Bates MP, Pinkus G, Schlossman SF, Nadler LM (1984) Expression of human B cell associated antigens on leukemias and lymphomas. Blood 63: 1424\u20131433","journal-title":"Blood"},{"key":"3_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJM199304083281409","volume":"328","author":"JO Armitage","year":"1993","unstructured":"Armitage JO (1993) Treatment of non-Hodgkin\u2019s lymphoma. N Engl J Med 328: 1023\u20131030","journal-title":"N Engl J Med"},{"key":"3_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1084\/jem.178.3.1023","volume":"178","author":"D Billadeau","year":"1993","unstructured":"Billadeau D, Ahmann G, Greipp G, Van Ness B (1993) The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 178: 1023\u20131031","journal-title":"J Exp Med"},{"key":"3_CR4","first-page":"947","volume":"47","author":"DC Blakey","year":"1987","unstructured":"Blakey DC, Watson GJ, Knowles PP, Thorpe PE (1987) Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A-chain and anti-Thy 1.1 antibody. Cancer Res 47: 947\u2013952","journal-title":"Cancer Res"},{"key":"3_CR5","volume-title":"Cancer: principles and practice of oncology","author":"PA Bunn Jr","year":"1993","unstructured":"Bunn PA Jr, Hoppe RT (1993) Cutaneous lymphomas. In: Devita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, fourth edition. Lippincott, Philadelphia","edition":"4"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0192-0561(94)90117-1","volume":"16","author":"AR Collinson","year":"1994","unstructured":"Collinson AR, Lambert JM, Liu Y, O\u2019Dea C, Shah SA, Rasmussen RA, Goldmacher VS (1994) anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin. Int J Immunopharmacol 16: 37\u201349","journal-title":"Int J Immunopharmacol"},{"key":"3_CR7","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1016\/S0021-9258(18)45660-8","volume":"262","author":"Y Endo","year":"1987","unstructured":"Endo Y, Mitsui K, Motizuki M, Tsurugi K (1987) The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J Biol Chem 262: 5908\u20135912","journal-title":"J Biol Chem"},{"key":"3_CR8","first-page":"862","volume":"44","author":"G Kvalheim","year":"1984","unstructured":"Fodstad O, Kvalheim G, Godal A, Lotsberg J, Aamdal S, Host H, Pihl A (1984) Phase I study of the plant protein ricin. Cancer Res 44: 862\u2013865","journal-title":"Cancer Res"},{"key":"3_CR9","first-page":"926","volume":"56","author":"AE Frankel","year":"1996","unstructured":"Frankel AE, FitzGerald D, Siegall C, Press OW (1996) Advances in immunotoxin biology and therapy: asummary of the 4th international symposium on immunotoxins. Cancer Res 56: 926\u2013932","journal-title":"Cancer Res"},{"key":"3_CR10","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1200\/JCO.1993.11.10.1841","volume":"11","author":"AS Freedman","year":"1993","unstructured":"Freedman AS, Nadler LM (1993) Which patients with relapsed non-Hodgkin\u2019s lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? J Clin Oncol 11: 1841\u20131843","journal-title":"J Clin Oncol"},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/0006-291X(92)90548-Y","volume":"183","author":"VS Goldmacher","year":"1992","unstructured":"Goldmacher VS, Lambert JM, Blattler WA (1992) The specific cytotoxicity of immunoconjugates containing blocked ricin is dependent on the residual binding capacity of blocked ricin: evidence that the membrane binding and A-chain translocation activities of ricin cannot be separated. Biochem Biophys Res Commun 183: 758\u2013766","journal-title":"Biochem Biophys Res Commun"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/jnci\/81.10.775","volume":"81","author":"BJ Gould","year":"1989","unstructured":"Gould BJ, Borowitz MJ, Groves ES, Carter PW, Anthony D, Weiner LM, Frankel AE (1989) Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst 81: 775\u2013781","journal-title":"J Natl Cancer Inst"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.4049\/jimmunol.130.6.2947","volume":"130","author":"JD Griffin","year":"1983","unstructured":"Griffin JD, Hercend T, Beveridge RP, Schlossman SF (1983) Characterization of an antigen expressed by human natural killer cells. J Immunol 130: 2947\u20132951","journal-title":"J Immunol"},{"key":"3_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0145-2126(84)90001-8","volume":"8","author":"JD Griffin","year":"1984","unstructured":"Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF (1984) A monoclonal antibody reactive with normal and leukemic progenitor cells. Leuk Res 8: 521\u2013534","journal-title":"Leuk Res"},{"key":"3_CR15","first-page":"1992","volume-title":"Important advances in oncology","author":"ML Grossbard","year":"1992","unstructured":"Grossbard ML, Nadler LM (1992) Immunotoxin therapy of malignancy. In: Devita VT Jr, Hellman S, Rosenberg SA (eds) Important advances in oncology 1992. Lippincott, Philadelphia"},{"key":"3_CR16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood.V79.3.576.576","volume":"79","author":"ML Grossbard","year":"1992","unstructured":"Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blattler WA, Taylor JA, Nadler LM (1992a) Serotherapy of B cell neoplasms with anti-B4blocked ricin. Blood 79: 576\u2013585","journal-title":"Blood"},{"key":"3_CR17","first-page":"4200","volume":"52","author":"ML Grossbard","year":"1992","unstructured":"Grossbard ML, Lambert JM, Goldmacher VS, Blattler WA, Nadler LM (1992b) Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin. Cancer Res 52: 4200\u20134207","journal-title":"Cancer Res"},{"key":"3_CR18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V80.4.863.863","volume":"80","author":"ML Grossbard","year":"1992","unstructured":"Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM (1992c) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80: 863\u2013878","journal-title":"Blood"},{"key":"3_CR19","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1182\/blood.V81.9.2263.2263","volume":"81","author":"ML Grossbard","year":"1993","unstructured":"Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blattler WA, Epstein CL, Nadler LM (1993a) Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B cell non-Hodgkin\u2019s lymphoma. Blood 81: 2262\u20132271","journal-title":"Blood"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.1993.11.4.726","volume":"11","author":"ML Grossbard","year":"1993b","unstructured":"Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blattler WA, Epstein CL, Nadler LM (1993b) anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B cell neoplasms. J Clin Oncol 11: 726\u2013737","journal-title":"J Clin Onco"},{"key":"3_CR21","first-page":"293","volume":"13","author":"ML Grossbard","year":"1994","unstructured":"Grossbard ML, O\u2019Day S, Gribben JG, Kolesar C, Freedman AS, Rabinowe SN, Neuberg D, Esseltine DL, Epstein CL, Nadler LM (1994) A phase II study of anti-B4-blocked ricin therapy following autologous bone marrow transplantation ( ABMT) for B cell non-Hodgkin\u2019s lymphoma. Proc Am Soc Clin Oncol 13: 293","journal-title":"Proc Am Soc Clin Oncol"},{"key":"3_CR22","first-page":"422","volume":"14","author":"ML Grossbard","year":"1995","unstructured":"Grossbard ML, Fidias P, Bernstein ZP, Vose J, Schuster M, Foon KA, Esseltine DL, Anderson KC, Nadler LM (1995) Phase II studies of anti-B4-blocked ricin (Anti-B4-bR) in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). Proc ASCO 14: 422","journal-title":"Proc ASCO"},{"key":"3_CR23","first-page":"7022","volume":"48","author":"RK Jain","year":"1988","unstructured":"Jain RK, Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48: 7022\u20137032","journal-title":"Cancer Res"},{"key":"3_CR24","first-page":"288","volume":"14","author":"L Kaplan","year":"1995","unstructured":"Kaplan L, Straus D, Testa M, Levine AM (1995) Randomized trial of standard dose mBACOD with GM-CSF vs reduced dose mBACOD for systemic HIV-associated lymphoma. Proc Am Soc Clin Oncol 14: 288","journal-title":"Proc Am Soc Clin Oncol"},{"key":"3_CR25","first-page":"6236","volume":"51","author":"JM Lambert","year":"1991","unstructured":"Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blattler WA (1991a) An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res 51: 6236\u20136242","journal-title":"Cancer Res"},{"key":"3_CR26","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1021\/bi00227a011","volume":"30","author":"JM Lambert","year":"1991","unstructured":"Lambert JM, McIntyre G, Gauthier MN, Zullo D, Rao V, Steeves RM, Goldmacher VS, Blattler WA (1991b) The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry 30: 3234\u20133247","journal-title":"Biochemistry"},{"key":"3_CR27","first-page":"442","volume":"20","author":"VF La Russa","year":"1992","unstructured":"La Russa VF, Griffin JD, Kessler SW, Cutting MA, Knight RD, Blattler WA, Lambert JM, Wright DG (1992) Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. Exp Hematol 20: 442\u2013448","journal-title":"Exp Hematol"},{"key":"3_CR28","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1182\/blood.V78.5.1173.1173","volume":"78","author":"CF LeMaistre","year":"1991","unstructured":"LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Drasjek J, Fishwild D, Scannon P, Byers V (1991) Phase I trial of H65-RTA immunoconjugate in patients with T-cell lymphoma. Blood 78: 1173\u20131182","journal-title":"Blood"},{"key":"3_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jama.266.1.84","volume":"266","author":"AM Levine","year":"1991","unstructured":"Levine AM, Wernz JC, Kaplan L, Rodman N, Cohen P, Metroka C, Bennett JM, Rarick MU, Walsh C, Kahn J, Miles S, Ehmann WC, Feinberg J, Nathwani B, Gill PS, Mitsuyasu R (1991) Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. JAMA 266: 84\u201388","journal-title":"JAMA"},{"key":"3_CR30","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood.V87.9.3892.bloodjournal8793892","volume":"87","author":"C Liu","year":"1996","unstructured":"Liu C, Lambert JM, Teicher BA, Blattler WA, O\u2019Connor R (1996) Cure of multidrug-resistant human B cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Blood 87: 3892\u20133898","journal-title":"Blood"},{"key":"3_CR31","first-page":"424","volume":"14","author":"TJ Lynch","year":"1995","unstructured":"Lynch TJ, Grossbard M, Fidias P, Bartholomay M, Coral F, Salgia R, Elias AD, Skarin A, Sheffner J, Wen P, Arinello P, Bramen G, Esseltine D, Ritz J (1995) Immunotoxin therapy of small cell lung cancer (SCLC): clinical trials of N901-blocked ricin (N901-bR). Proc Am Soc Clin Oncol 14: 424","journal-title":"Proc Am Soc Clin Oncol"},{"key":"3_CR32","first-page":"1501","volume":"35","author":"P McLaughlin","year":"1994","unstructured":"McLaughlin P, Murray JL, Rosenblum M, Brewer H, LeBherz D, O\u2019Brien S, Hagemeister FB, Epstein C, Esseltine D, Keating M (1994) Phase I trial of anti-B4-blocked ricin (B4bR) by 28-day, continuous infusion (CI). Proc AACR 35: 1501","journal-title":"Proc AACR"},{"key":"3_CR33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4049\/jimmunol.131.1.244","volume":"131","author":"LM Nadler","year":"1983","unstructured":"Nadler LM, Anderson KC, Marti G, Bates MP, Park E, Daley JF, Schlossman SF (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B-lymphocytes. J Immunol 131: 244\u2013250","journal-title":"J Immunol"},{"key":"3_CR34","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1182\/blood.V86.11.4286.bloodjournal86114286","volume":"86","author":"R O\u2019Connor","year":"1995","unstructured":"O\u2019Connor R, Liu C, Ferris CA, Guild BC, Teicher BA, Corvi C, Liu Y, Arceci RJ, Goldmacher VS, Lambert JM, Blattler WA (1995) anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 86: 4286\u20134294","journal-title":"Blood"},{"key":"3_CR35","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.1991.9.12.2095","volume":"9","author":"LH Pai","year":"1991","unstructured":"Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW II, Longo DL, Gould B, Frankel A, McClay EF, Howell S, Reed E, Willingham MC, Fitzgerald DJ, Pastan I (1991) Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate of OVB3-PE in patients with ovarian cancer. J Clin Oncol 9: 2095\u20132103","journal-title":"J Clin Oncol"},{"key":"3_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/canjclin.46.1.5","volume":"46","author":"SL Parker","year":"1996","unstructured":"Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer statistics 1996. CA Cancer J Clin 46: 5\u201327","journal-title":"CA Cancer J Clin"},{"key":"3_CR37","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn J-Y, Harousseau J-L, Coiffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 333: 1540\u20131545","journal-title":"N Engl J Med"},{"key":"3_CR38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7326\/0003-4819-113-4-276","volume":"113","author":"JM Pluda","year":"1990","unstructured":"Pluda JM, Yarchoan R, Jaffe ES, Feuerstein IM, Solomon D, Steinberg SM, Wyvill KM, Raubitschek A, Katz D, Broder S (1990) Development of non-Hodgkin\u2019s lymphoma in a cohort of patients with severe human immunodeficiency virus ( HIV) infection on long-term anti retroviral therapy. Ann Intern Med 113: 276\u2013282","journal-title":"Ann Intern Med"},{"key":"3_CR39","first-page":"82","volume":"640","author":"MJ Robertson","year":"1993","unstructured":"Robertson MJ, Roy DC, Soiffer R, Belanger R, Gyger M, Perreault C, Anderson K, Freedman A, Nadler LM, Ritz J (1993) More rapid engraftment after infusion of autologous bone marrow treated with anti-My9-blocked ricin compared to bone marrow treated with Ant-My9 and complement. Blood 82: 640a","journal-title":"Blood"},{"key":"3_CR40","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1182\/blood.V77.11.2404.2404","volume":"77","author":"DC Roy","year":"1991","unstructured":"Roy DC, Griffin JD, Belvin M, Blattler WA, Lambert JM, Ritz J (1991) anti-My9-blocked ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood 77: 2404\u20132412","journal-title":"Blood"},{"key":"3_CR41","volume-title":"Update on anti-My9-bR depleted autologous bone marrow transplantation for patients with acute myeloid leukemia. XVIIIth congress of the Association of Hematologists-Oncologists of Quebec","author":"DC Roy","year":"1993","unstructured":"Roy DC, Robertson MJ, Belanger R, Gyger M, Perreault C, Bonny Y, Soiffer R, Epstein C, Esseltine D, Ritz J (1993) Update on anti-My9-bR depleted autologous bone marrow transplantation for patients with acute myeloid leukemia. XVIIIth congress of the Association of Hematologists-Oncologists of Quebec"},{"key":"3_CR42","volume-title":"High dose therapy in non-Hodgkin\u2019s lymphoma using anti-B4-bR immunotoxin purging","author":"DC Roy","year":"1995","unstructured":"Roy DC, Belanger R, Perrault C, Bonny Y, Busque L, Kassis J, Boileau J, Lavalee R, Guertin MJ, D\u2019Angelo G, Esseltine D, Gyger M (1995a) High dose therapy in non-Hodgkin\u2019s lymphoma using anti-B4-bR immunotoxin purging. 4th international symposium on immunotoxins, Myrtle Beach, SC"},{"key":"3_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF01489490","volume":"15","author":"DC Roy","year":"1995","unstructured":"Roy DC, Perreault C, Belanger R, Gyger M, Le Houillier C, Blattler WA, Lambert JM, Ritz J (1995b) Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4blocked ricin immunotoxin. J Clin Immunol 15: 51\u201357","journal-title":"J Clin Immunol"},{"key":"3_CR44","volume-title":"Cancer: principles and practice of oncology","author":"SE Salmon","year":"1993","unstructured":"Salmon SE, Cassady JR (1993) Plasma cell neoplasms. In: Devita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, fourth edition. Lippincott, Philadelphia","edition":"4"},{"issue":"1","key":"3_CR45","first-page":"386a","volume":"82","author":"DT Scadden","year":"1993","unstructured":"Scadden DT, Doweiko J, Schenkein D, Bernstein Z, Levine AM, Bresnahan J, Gere J, Esseltine D, Epstein CA (1993) A phase I\/II trial of combined immunoconjugate and chemotherapy for AIDS-related lymphoma. Blood 82 [Suppl 1]: 386a","journal-title":"Blood"},{"key":"3_CR46","first-page":"783a","volume":"86","author":"TP Szatrowski","year":"1995","unstructured":"Szatrowski TP, Larson RA, George S, Dodge R, Hurd D, Kolitz J, Velez-Garcia E, Sklar J, Reynolds C, Westbrook CA, Frankel SR, Stewart C, Bloomfield CD, Schiffer CA (1995) anti-B4-blocked Ricin as consolidation therapy for patients with B-lineage acute lymphoblastic leukemia (ALL): a phase II trial (CALGB 9311). Blood 86[Suppl 1]:783a","journal-title":"Blood"},{"key":"3_CR47","first-page":"52","volume":"13","author":"A Tulpule","year":"1994","unstructured":"Tulpule A, Anderson LJJ, Levine AM, Espina B, Esplin J, Boswell W, Scadden D, Esseltine D, Epstein CL (1994) anti-B4 (CD19) monoclonal antibody conjugated with ricin (B4-blocked ricin: B4bR) in refractory AIDS lymphoma. Proc Am Soc Clin Oncol 13: 52","journal-title":"Proc Am Soc Clin Oncol"},{"key":"3_CR48","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.3317828","volume":"238","author":"ES Vitetta","year":"1987","unstructured":"Vitetta ES, Fulton RJ, May RD, Till M, Uhr J (1987) Redesigning nature\u2019s poisons to create anti-tumor reagents. Science 238: 1098\u20131104","journal-title":"Science"},{"key":"3_CR49","first-page":"4052","volume":"51","author":"ES Vitetta","year":"1991","unstructured":"Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr JW, Thorpe PE (1991) Phase I immunotoxin trial in patients with B cell lymphoma. Cancer Res 51: 4052\u20134058","journal-title":"Cancer Res"},{"key":"3_CR50","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJM198711053171904","volume":"317","author":"LM Weiss","year":"1987","unstructured":"Weiss LM, Warnke RA, Sklar J, Cleary ML (1987) Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 317: 1185\u20131189","journal-title":"N Engl J Med"},{"key":"3_CR51","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1056\/NEJM198211113072002","volume":"307","author":"JJ Yunis","year":"1982","unstructured":"Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR (1982) Distinctive chromosomal abnormalities in histological subtypes of non-Hodgkin\u2019s lymphoma. N Engl J Med 307: 1231\u20131236","journal-title":"N Engl J Med"}],"container-title":["Current Topics in Microbiology and Immunology","Clinical Applications of Immunotoxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-72153-3_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:35:37Z","timestamp":1683826537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-72153-3_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998]]},"ISBN":["9783642721557","9783642721533"],"references-count":51,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-72153-3_3","relation":{},"ISSN":["0070-217X"],"issn-type":[{"type":"print","value":"0070-217X"}],"subject":[],"published":{"date-parts":[[1998]]}}}